Orchestra BioMed Holdings, Inc. $OBIO

What the company doesAI summary of filing

Orchestra BioMed Holdings, Inc. is a biomedical innovation company developing late-stage clinical medical device product candidates through partnerships with major device manufacturers. The company's two flagship products are AVIM Therapy, a bioelectronic treatment for hypertension in pacemaker-indicated patients, which is being developed with exclusive partner Medtronic through the ongoing BACKBEAT pivotal study; and Virtue SAB, a drug-device combination balloon for treating arterial disease, which is in a pivotal trial sponsored by the FDA. Orchestra BioMed operates on a partnership-enabled business model in which it focuses on advancing product candidates through clinical development while partners handle commercialization, and the company receives royalties or revenue-share payments from product sales if approved. The company is clinical-stage, pre-revenue, with development programs supported by strategic partners and investors including Medtronic, Terumo Corporation, and Ligand Pharmaceuticals. [10-K 2026-03-12]

Segments: AVIM Therapy (hypertension treatment), Virtue SAB (coronary and peripheral artery disease), CNT-HF (heart failure), SirolimusEFR (local inflammation treatment platform)